Jaber Tariq M, Samiullah Mohammad, Surti Amy
Infectious Diseases, Allegheny Health Network, Pittsburgh, USA.
Internal Medicine, Broward Health General, Fort Lauderdale, USA.
Cureus. 2021 Apr 20;13(4):e14589. doi: 10.7759/cureus.14589.
Transitional cell carcinoma is the sixth most common cancer among men and the 17th most common cancer in women. The treatment methods for the condition range from noninvasive chemotherapy to more invasive procedures like cystectomy and complete transurethral resection of bladder tumor (TURBT) followed by intravesical Bacillus Calmette-Guérin (BCG) therapy (BCG). Intravesical BCG treatment is known to be effective as it is associated with increased survivability and long-term benefits, especially in early-stage, minimally-invasive disease. It is generally considered to be safe, even though some adverse reactions have been described. Vertebral osteomyelitis secondary to intravesical BCG therapy is a rare complication but one that has been reported in the literature. Although our patient had multiple comorbidities, including a previous vertebral compression fracture prior to treatment, complications from intravesical BCG treatment should always be considered in the differential. Further multi-center retrospective studies are needed to better ascertain its true risk given its increasing use as a treatment modality for transitional cell carcinoma.
移行细胞癌是男性中第六大常见癌症，在女性中是第17大常见癌症。该疾病的治疗方法从非侵入性化疗到更具侵入性的手术，如膀胱切除术和完全经尿道膀胱肿瘤切除术（TURBT），随后进行膀胱内卡介苗（BCG）治疗（卡介苗）。膀胱内卡介苗治疗已知是有效的，因为它与生存率提高和长期益处相关，特别是在早期、微创疾病中。尽管已经描述了一些不良反应，但它通常被认为是安全的。膀胱内卡介苗治疗继发的脊椎骨髓炎是一种罕见的并发症，但文献中已有报道。虽然我们的患者有多种合并症，包括治疗前既往有椎体压缩性骨折，但在鉴别诊断时应始终考虑膀胱内卡介苗治疗的并发症。鉴于其作为移行细胞癌治疗方式的使用越来越多，需要进一步的多中心回顾性研究以更好地确定其真正风险。
